REPORT ON THE CLINICAL STUDY OF THE EFFECTIVENESS OF "T-98" IN PATIENTS WITH BREAST CANCER

Abbreviated Version
Original Report: DOWNLOAD

Study Object
Patients with breast cancer.

Study Objective
The aim of the study was to evaluate changes in breast cancer patients during clinical and laboratory examinations while using the dietary supplement "SIBITAX® T-98" for 12 weeks.

Methodology
The study included 31 women with an average age of 53.46 ± 7.56 years. The control group consisted of 16 women who did not receive the dietary supplement but underwent anticancer therapy, with an average age of 49 ± 6.33 years. All participants were diagnosed with breast cancer.

Main Results

• Safety and Tolerability: The dietary supplement "SIBITAX® T-98" is safe and well-tolerated by patients in the comprehensive treatment of breast cancer.
• Patient Satisfaction: The overall satisfaction score with the supplement was 5.9 ± 1.1 points.
• Biochemical Changes: There was a statistically significant decrease in total bilirubin levels in the blood biochemical analysis (p = 0.0024) during the use of "SIBITAX® T-98".
• Kidney Function: The absence of protein and bilirubin in urine tests indicates a positive effect of the supplement on kidney function.
• Quality of Life: Positive dynamics were observed regarding symptoms such as reduced pain in the area of surgical intervention, weakness, discomfort when moving the arm on the affected side, increased energy for daily life, and improved sleep.

Statistical Data

• Leukocytes: 5.04 ± 1.05 before treatment and 4.93 ± 1.26 after treatment (p > 0.05).
• Erythrocytes: 4.50 ± 0.27 before treatment and 4.42 ± 0.24 after treatment (p > 0.05).
• Hemoglobin: 131.07 ± 5.76 before treatment and 136.56 ± 12.56 after treatment (p > 0.05).
• Platelets: 240 ± 51.46 before treatment and 211.2 ± 41.72 after treatment (p = 0.0027).
• Lymphocytes: 32 ± 6.38 before treatment and 21.30 ± 6.81 after treatment (p = 0.0010).

Conclusion
The study demonstrated that "SIBITAX® T-98" improves blood and liver function indicators and the quality of life of patients with breast cancer without recording adverse events. The use of this supplement can be recommended as an additional means in the comprehensive therapy of breast cancer.

Practical Recommendations
To reduce symptoms arising from comprehensive breast cancer therapy, it is recommended to use "SIBITAX® T-98" at a dose of 1 capsule twice daily (morning and evening) for 3 months.

References

• Vysotskaya I.V. Endocrine-sensitive tumors of the reproductive system: A guide for doctors. M.: Special Publishing House of Medical Books (SIMK). 2014. 126 p.
• Amin M.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging // CA. Cancer J. Clin. 2017. Vol. 67, No. 2. P. 93-99.
• Mayer I et al. (PDF) Breast cancer version 3.2014 | Ingrid Mayer - Academia.edu [Electronic resource]. URL: Breast Cancer Version 3.2014 (accessed: 14.12.2019).
• Hassan L.M. et al. Evaluation of effect of self-examination and physical examination on breast cancer // Breast Edinb. Scotl. 2015. Vol. 24, No. 4. P. 487-490.
• Malignant neoplasms in Russia in 2017 (incidence and mortality). Ed. A.D. Kaprin, V.V. Starinsky, G.V. Petrova. M.: P.A. Herzen Moscow Cancer Research Institute, a branch of the Federal State Budgetary Institution "NMRRC" of the Ministry of Health of Russia, 2018. 250 p.
• Liu X, Meng QH, Ye Y. Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. - PubMed - NCBI. 2015. Vol. 36, No. 2. P. 243-248.
• Elyasinia F, Keramati MR, Ahmadi F. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer. - // Acta Med Iran. 2017. Vol. 55, No. 4. P. 228-232.
• Vernieri C, Mennitto A3, Prisciandaro M. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple-negative breast cancer. // Sci Rep. 2018. Vol. 8, No. 1. P. 8703.
• Lindkær-Jensen S. et al. Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance // Drug Des. Devel. Ther. 2015. Vol. 9. P. 1481-1490.
• Tas F., Kilic L., Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer // Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 2014. Vol. 35, No. 6. P. 5985-5992.
• Pedersen L.M., Sørensen P.G. Increased urinary albumin excretion rate in breast cancer patients // Acta Oncol. Stockh. Swed. 2000. Vol. 39, No. 2. P. 145-149.
• Hammond M.E.H. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.